PMI’s acquisition of Fertin Pharma, a Danish manufacturer of gums and other oral products, indicates the company’s strategy to ensure “corporate survival” in the tobacco-alternatives sector, experts believe
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis.